On Tuesday, European Union (EU) antitrust regulators conducted surprise inspections at a cardiovascular medical device company located within an EU member state. These actions were taken due to concerns that the company may have engaged in practices that abused its market dominance, potentially violating the EU’s antitrust regulations.
In an official statement, the EU’s competition enforcement body, the European Commission, confirmed these unannounced visits to the company’s premises. The statement explained that the Commission was investigating the company’s activities in the field of medical devices for cardiovascular applications and expressed concerns that the company might have breached EU antitrust rules prohibiting the misuse of a dominant market position.
The European Commission, serving as the antitrust authority for the 27 EU member countries, adhered to its policy of not disclosing the specific company or the country involved. It’s important to note that companies found to have violated EU antitrust laws can face fines of up to 10% of their global turnover.
These surprise inspections or ‘Dawn Raids’ are often among the first steps in the investigative process when there are suspicions of anticompetitive behavior. It should be noted that the Commission’s actions do not presuppose the company’s guilt regarding anticompetitive practices, nor do they predetermine the outcome of the ongoing investigation.
Related: EC Europa
Featured News
Big Tech Braces for Potential Changes Under a Second Trump Presidency
Nov 6, 2024 by
CPI
Trump’s Potential Shift in US Antitrust Policy Raises Questions for Big Tech and Mergers
Nov 6, 2024 by
CPI
EU Set to Fine Apple in First Major Enforcement of Digital Markets Act
Nov 5, 2024 by
CPI
Six Indicted in Federal Bid-Rigging Schemes Involving Government IT Contracts
Nov 5, 2024 by
CPI
Ireland Secures First €3 Billion Apple Tax Payment, Boosting Exchequer Funds
Nov 5, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Remedies Revisited
Oct 30, 2024 by
CPI
Fixing the Fix: Updating Policy on Merger Remedies
Oct 30, 2024 by
CPI
Methodology Matters: The 2017 FTC Remedies Study
Oct 30, 2024 by
CPI
U.S. v. AT&T: Five Lessons for Vertical Merger Enforcement
Oct 30, 2024 by
CPI
The Search for Antitrust Remedies in Tech Leads Beyond Antitrust
Oct 30, 2024 by
CPI